MX358050B - Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. - Google Patents

Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.

Info

Publication number
MX358050B
MX358050B MX2013005016A MX2013005016A MX358050B MX 358050 B MX358050 B MX 358050B MX 2013005016 A MX2013005016 A MX 2013005016A MX 2013005016 A MX2013005016 A MX 2013005016A MX 358050 B MX358050 B MX 358050B
Authority
MX
Mexico
Prior art keywords
nucleic acid
methods
compositions
nanopolymer
acid delivery
Prior art date
Application number
MX2013005016A
Other languages
English (en)
Other versions
MX2013005016A (es
Inventor
N Vournakis John
V Demcheva Marina
Original Assignee
Marine Polymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Tech Inc filed Critical Marine Polymer Tech Inc
Publication of MX2013005016A publication Critical patent/MX2013005016A/es
Publication of MX358050B publication Critical patent/MX358050B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a las composiciones nanopartícula/ácido nucleico p-GlcNAc. En un aspecto, las composiciones de nanopartícula/ácido nucleico p-GlcNAc contienen nanopartículas de derivado polilactato de N-acetilgiucosamina desacetilado de menos de 500 nm y un ácido nucleico. Asimismo, en la presente se proporcionan los métodos para administrar un ácido nucleico a un individuo, el método consiste en administrar al individuo una composición nanopartícula/ácido nucleico p-GlcNAc. En ciertas modalidades, la composición de nanopartícula/ácido nucleico p-GlcNAc se administra por vía subcutánea al individuo.
MX2013005016A 2010-11-06 2011-11-07 Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. MX358050B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US41135810P 2010-11-08 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (2)

Publication Number Publication Date
MX2013005016A MX2013005016A (es) 2014-03-12
MX358050B true MX358050B (es) 2018-08-03

Family

ID=46025153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005016A MX358050B (es) 2010-11-06 2011-11-07 Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.

Country Status (10)

Country Link
US (3) US20130287853A1 (es)
EP (1) EP2635261B1 (es)
JP (2) JP6029591B2 (es)
CN (2) CN103282024A (es)
AU (3) AU2011323078B2 (es)
CA (1) CA2816999A1 (es)
ES (1) ES2763432T3 (es)
IL (1) IL226170B (es)
MX (1) MX358050B (es)
WO (1) WO2012061803A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2621018T3 (es) 2007-02-19 2017-06-30 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
JP6029591B2 (ja) * 2010-11-06 2016-11-24 マリン ポリマー テクノロジーズ，インコーポレーテッド ナノポリマーをベースとした核酸送達のための組成物および方法
CN107362171A (zh) 2011-04-15 2017-11-21 海洋聚合物技术公司 用聚‑n‑乙酰基葡糖胺纳米纤维治疗疾病
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US20060105049A1 (en) * 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
CA2676919C (en) * 2007-01-31 2013-01-29 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
EP2569017A4 (en) * 2010-05-10 2013-10-02 Ecole Polytech GENE THERAPY FOR DIABETES WITH CHITOSAN-MEDIATED PLASMIDE FOR CODING FOR THE GLUCAGON-SIMILAR PEPTIDE 1
JP6029591B2 (ja) * 2010-11-06 2016-11-24 マリン ポリマー テクノロジーズ，インコーポレーテッド ナノポリマーをベースとした核酸送達のための組成物および方法

Also Published As

Publication number Publication date
JP2016164181A (ja) 2016-09-08
IL226170B (en) 2018-11-29
EP2635261A2 (en) 2013-09-11
ES2763432T3 (es) 2020-05-28
EP2635261B1 (en) 2019-10-23
CN108743562A (zh) 2018-11-06
CN103282024A (zh) 2013-09-04
US20130287853A1 (en) 2013-10-31
MX2013005016A (es) 2014-03-12
US20230157971A1 (en) 2023-05-25
AU2011323078B2 (en) 2016-04-14
WO2012061803A2 (en) 2012-05-10
IL226170A0 (en) 2013-07-31
AU2016201640A1 (en) 2016-04-07
JP6029591B2 (ja) 2016-11-24
US20170128382A1 (en) 2017-05-11
EP2635261A4 (en) 2014-09-17
AU2013203247A1 (en) 2013-05-09
CA2816999A1 (en) 2012-05-10
WO2012061803A3 (en) 2012-08-16
JP2014500250A (ja) 2014-01-09
AU2011323078A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
MX358050B (es) Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.
MX342439B (es) Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos.
NZ604063A (en) Compositions and methods for enhancing physiological performance and recovery time
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MY173008A (en) Methods and compositions for improving gut microbiota population
IN2014KN00996A (es)
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2013041975A3 (en) Pyrethroid formulations
WO2010075072A3 (en) Long circulating nanoparticles for sustained release of therapeutic agents
IL227623B (en) Preparations of extremely tiny particles containing a population of particles, for use in creating a medicine for topical treatment in patients who suffer or tend to suffer from a disease related to the sweat glands and/or the mammary glands
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
MX345404B (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol- 2-il]-1h-quinolin-2-ona.
NZ595987A (en) A novel formulation of diclofenac
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2012047733A3 (en) Treatment of acne by conditioned media
WO2011069010A3 (en) Amantadine compositions and methods of use
WO2013087734A3 (en) Functionalised silicon nanoparticles
WO2012121528A3 (en) Magnetic nanocomposite specific for thyroid cancer and use thereof
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
MY165003A (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
NZ722319A (en) A novel formulation of meloxicam

Legal Events

Date Code Title Description
FG Grant or registration